A naukri.com initiative
Bioengineer
2w
238
Image Credit: Bioengineer
City of Hope Researchers to Unveil Promising Cancer Advances Aiming to Improve Survival at ASCO Annual Meeting
- City of Hope will unveil groundbreaking advances in oncology at the 2025 ASCO Annual Meeting, focusing on breast, genitourinary, and gastrointestinal cancers.
- A key study explores rechallenging metastatic breast cancer patients with trastuzumab-deruxtecan post-ILD, showing feasible rechallenge with substantial benefits and emphasizing timely immunomodulatory interventions.
- Research on renal cell carcinoma reveals insights into genomic evolution and recurrence patterns, identifying molecular subgroups with prolonged survival benefits from immunotherapy.
- In colorectal cancer, a Phase 2 trial of dual checkpoint inhibition shows tumor shrinkage in MSS-colorectal cancer patients, traditionally unresponsive to immunotherapy.
- A study on cardiovascular outcomes in mCRPC patients highlights elevated risks with abiraterone acetate compared to enzalutamide, underscoring the need for careful therapeutic selection.
- City of Hope’s research presents personalized oncology solutions based on real-world evidence and molecular diagnostics, shaping future therapeutic landscapes.
- The institution's holistic research agenda aims to transform hope into reality by advancing breakthrough treatments and supportive care interventions.
- As oncology advances, City of Hope's initiatives demonstrate the value of real-world data, genomics, and novel therapeutics in defining tailored treatment protocols.
- The 2025 ASCO Annual Meeting will showcase these achievements, fostering collaborations and progress toward overcoming cancer challenges.
- City of Hope's commitment to innovative cancer care extends to reducing cancer risk and enhancing survivorship outcomes, encompassing various cancer types.
Read Full Article
14 Likes
For uninterrupted reading, download the app